Trial · NCT03467373
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part I: Percentage of Participants with Dose Limiting Toxicities (DLTs) | Up to 29 months | |
| Primary | Part I and II: Percentage of Participants with Adverse Events | Up to 29 months | |
| Secondary | Parts I and II: Percentage of Participants with a Complete Response (CR) as Assessed by the Investigator using Modified Lugano 2014 Criteria | Up to 29 months | |
| Secondary | Parts I and II: Percentage of Participants with Overall Response (Partial Response [PR] or Complete Response [CR]) | Up to 29 months | |
| Secondary | Parts I and II: Duration of Response (DOR) | Up to 29 months | |
| Secondary | Duration of CR | Up to 29 months | |
| Secondary | Progression-Free Survival (PFS) | Up to 29 months | |
| Secondary | Overall Survival (OS) | Up to 29 months | |
| Secondary | Time to First Complete Response (TFCR) | Up to 29 months | |
| Secondary | Time to First Response (TFOR) | Up to 29 months | |
| Secondary | Parts I and II: Area Under the Serum Concentration Versus Time Curve (AUC) of Glofitamab | Cycle 1 Day 1 up to 29 months | |
| Secondary | Parts I and II: Time to Maximum Serum Concentration (tmax) of Glofitamab | Cycle 1 Day 1 up to 29 months | |
| Secondary | Parts I and II: Maximum Serum Concentration (Cmax) of Glofitamab | Cycle 1 Day 1 up to 29 months | |
| Secondary | Parts I and II: Minimum Serum Concentration (Cmin) of Glofitamab | Cycle 1 Day 1 up to 29 months | |
| Secondary | Change from Baseline in T-cell Activation Markers | Up to 29 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03467373/registered